- Home
- CERS vs UPB Comparison
CERS vs UPB Comparison
Compare CERS & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- UPB
- Stock Information
- Founded
- CERS 1991
- UPB 2021
- Country
- CERS United States
- UPB United States
- Employees
- CERS N/A
- UPB N/A
- Industry
- CERS EDP Services
- UPB
- Sector
- CERS Technology
- UPB
- Exchange
- CERS Nasdaq
- UPB NYSE
- Market Cap
- CERS 347.3M
- UPB 402.8M
- IPO Year
- CERS 1997
- UPB 2024
- Fundamental
- Price
- CERS $1.30
- UPB $8.78
- Analyst Decision
- CERS Strong Buy
- UPB Strong Buy
- Analyst Count
- CERS 2
- UPB 4
- Target Price
- CERS $3.50
- UPB $56.50
- AVG Volume (30 Days)
- CERS 1.3M
- UPB 305.5K
- Earning Date
- CERS 05-01-2025
- UPB 05-14-2025
- Dividend Yield
- CERS N/A
- UPB N/A
- EPS Growth
- CERS N/A
- UPB N/A
- EPS
- CERS N/A
- UPB N/A
- Revenue
- CERS $180,270,000.00
- UPB $2,370,000.00
- Revenue This Year
- CERS $25.57
- UPB N/A
- Revenue Next Year
- CERS $10.54
- UPB $0.99
- P/E Ratio
- CERS N/A
- UPB N/A
- Revenue Growth
- CERS 15.29
- UPB N/A
- 52 Week Low
- CERS $1.12
- UPB $5.14
- 52 Week High
- CERS $2.54
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- CERS 42.68
- UPB N/A
- Support Level
- CERS $1.12
- UPB N/A
- Resistance Level
- CERS $1.42
- UPB N/A
- Average True Range (ATR)
- CERS 0.11
- UPB 0.00
- MACD
- CERS 0.01
- UPB 0.00
- Stochastic Oscillator
- CERS 58.06
- UPB 0.00
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.